Key result
CMV infection in active SLE linked to ~522% greater one-year mortality.
Why the study?
Factors associated with and treatment outcomes of CMV infection in patients with active systemic lupus erythematosus were not well characterized.
What are the clinical characteristics, prognosis, and treatment outcomes of CMV infection in patients with active systemic lupus erythematosus?
Cohort (n=103)
No
What are the clinical characteristics, prognosis, and treatment outcomes of CMV infection in patients with active systemic lupus erythematosus?
Relative Risk: 6.22 (95% CI 1.01–39.69)
Absolute Event Rate: 21.6% vs 1.5%
p-value: p=0.001
In patients with active SLE, CMV infection is associated with high disease activity, specific clinical features like proteinuria and low C3, and high-dose glucocorticoid use, with varying prognosis depending on the clinical presentation.
CMV infection may raise mortality in active SLE on immunosuppression; leaves open optimal screening and antiviral thresholds in prospective studies.
OBJECTIVE: To identify factors associated with, and treatment outcomes of Cytomegalovirus (CMV) infection in patients with active systemic lupus erythematosus (SLE). METHODS: SLE patients treated with glucocorticoids, with/without immunosuppressive drugs who still had persistently active disease, were identified. All patients who were suspected of having CMV infection and tested for CMV PCR were enrolled. Clinical and laboratory characteristics, SLE disease activity (SLEDAI-2 K) and treatment outcomes were collected. One-year mortality was compared between CMV-infected and non-infected patients. RESULTS: 103 SLE patients were included. Thirty-seven (35.9%) had CMV infection (DNAemia); CMV disease (group 1) n = 6, symptomatic CMV infection (group 2) n = 8 and CMV infection coexisting with active SLE (group 3) n = 23. Significant characteristics of patients with CMV infection included higher SLEDAI-2 K, proteinuria, lymphopenia, thrombocytopenia, AIHA, alopecia, pleuritis, low C3, higher prednisolone dose, treatment with mycophenolate mofetil and cyclosporine. Multivariable analysis revealed that proteinuria (OR6.95; 95%CI 1.29–37.59; p = 0.024), low C3 (OR5.30; 95%CI 1.09–25.76; p = 0.039) and 30-day-average prednisolone dose > 20 mg/day (OR8.01; 95%CI 1.54–41.63; p = 0.013) were associated with CMV infection. Among non-surviving patients, 8/9(88.9%) had CMV infection. CMV was the direct cause of death in 2 patients and indirect cause in 6 (bacterial sepsis and active disease). Despite ganciclovir treatment, mortality rate was higher in patients in group 1 (66%) compared to group 2 and group 3 (12%). However, fever, leucopenia, nephrotic syndrome, rapidly progressive glomerulonephritis and lung hemorrhage mimic lupus flare, can be reversed after antiviral treatment. CONCLUSIONS: Different clinical presentations, prognosis and clinical outcomes were identified in SLE patients with CMV infection. After treatment with antiviral therapy, symptomatic CMV infection was associated with the best prognosis. CMV disease was associated with worst prognosis. CMV infection coexisting with active SLE was the most common type of CMV infection in active SLE. This group was associated with variable prognosis according to the clinical context.
No takes yet. Share an insight, caveat, or question.
Sumethkul et al. (2025) conducted a cohort in Active systemic lupus erythematosus (SLE) with suspected CMV infection (n=103). Cytomegalovirus (CMV) infection vs. No CMV infection was evaluated on One-year mortality (RR 6.22, 95% CI 1.01-39.69, p=0.001). Cytomegalovirus infection in patients with active systemic lupus erythematosus significantly increased one-year mortality compared to non-infected patients (21.6% vs 1.5%, RR 6.22).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: